1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Asia-Pacific Liver Cancer Market - Segmented by type, technology, end-user and geography (2015 - 2020)

Mordor Intelligence analysts forecasted the Asia-Pacific Liver Cancer Market to grow at a CAGR of 7-15% over the amount 2015-2020. The market is currently valued at USD 141 million for the year 2015.

Asia represents the fastest growing liver cancer treatment market due to the increasing geriatric populations. The liver has a significant ability to regenerate and maintain functionality in elderly age. However, changes in cellular and physiological function during aging inhibit the normal functioning of the liver, which eventually leads to diseases. Furthermore, Asia has one of the strong oncology markets, accounting for nearly half of all new cancer cases in the world. These increasing cases of cancer also comprise of liver cancers. This growing number of liver cancer cases in the Asian countries require huge amount of drugs for the prevention and treatment of liver cancer and tumors.

With only a few approved drugs within the market and another few in the pipeline, it is a proven fact that incidence and mortality from the sickness continues to rise worldwide. Many new-targeted therapies are expected to enter the market in the following few years. Targeted cancer therapies use medication to prevent the expansion of cancer cells by interrupting certain molecules, known as molecular targets, thereby preventing the progression and growth of cancer cells. The treatment, also known as 'molecular targeted therapy', focuses on the cellular and molecular changes, pertaining specifically to cancer. It is thereby more effective, as compared to the other treatments for cancer, including radiotherapy and chemotherapy.

The Asia-Pacific Liver Cancer Market is segmented based on:

Benign liver growths
Ultrasound scans
Confirmatory needle biopsy
Endoscopic ultrasound
CT scan
PET scan
Magnetic resonance imaging (MRI) scans
Hepatocellular carcinoma
Targeted therapy

Some of the key participants in the industry include Bayer Schering Pharma AG, Onyx Pharmaceuticals, Inc., Celsion Corp., Alnylam Pharmaceuticals, Inc., ArQule, Inc., 4SC AG, ImClone Systems Inc., Jennerex Biotherapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Etc.


Increasing incidences of cancer
Drug innovations with regard to the cancer
Government initiatives
Rise in aging populace
Excessive alcohol consumptions
High unmet needs for the treatment of liver cancer in the market
Increasing health care expenditure
Emerging countries such as India and China presenting an array of opportunities


Low success rate in clinical trials for cancer drugs
Huge capital investments
Low accessibility in remote areas
Stringent regulatory procedures

Table Of Contents

Asia-Pacific Liver Cancer Market - Segmented by type, technology, end-user and geography (2015 - 2020)
1. Executive Summary

2. Research Methodology

3. Introduction

3.1 Report Description

3.2 Markets Covered

4. Market Overview

4.1 Market Definition

4.2 Market Drivers

4.2.1 aging population

4.2.2 Rising Government and Non-Government Funding for Vaccine Development

4.2.3 high unmet needs for the treatment of liver cancer

4.2.4 excessive alcohol consumptions

4.3 Market Restraints

4.3.1 Techinical Advancements

4.3.2 Huge Capital Investments

4.3.3 Stringent Regulatory Procedures

4.3.4 Low success rate in clinical trails for cancer drugs

4.4 Market Opportunitites

4.5 Market Threats

5. Porters Five Force Analysis

5.1 Bargaining Power of suppliers

5.2 Bargaining power of buyers

5.3 Degree of competition

5.4 Threat of substitution

5.5 Threat of new entrants

6. Market Segmentation

6.1 By Type

6.1.1 primary liver cancer Hepatocellular carcinoma (HCC) Angiosarcoma Cholangiocarcinoma (bile duct cancer) Hepatoblastoma

6.1.2 secondary liver cancer

6.1.3 Benign liver growths

6.2 Diagnosis

6.2.1 ultrasound scans

6.2.2 Confirmatory Needle biopsy

6.2.3 Endoscopic Ultrasound

6.2.4 Laparoscopy

6.2.5 CT Scan

6.2.6 PET Scan

6.2.7 magnetic resonance imaging (MRI) scans

6.3 Therapeutics

6.3.1 Hepatocellular carcinoma

6.3.2 Cholangiocarcinoma

6.3.3 Hepatoblastoma

6.3.4 Targeted therapy

6.3.5 Others

6.4 By End User

6.4.1 Pediatrics

6.4.2 Adults

6.5 By Geography

6.5.1 China

6.5.2 India

6.5.3 Japan

6.5.4 Australia

6.5.5 Singapore

7. Competitive Landscape

7.1 Mergers and Acquisitions

7.2 Agreements, Collaborations and Partnerships

7.3 New Product Launches

7.4 Recommendations to new market players

7.5 Value Chain Analysis

8. Company Profiles

8.1 Bayer Schering Pharma AG,

8.2 Onyx Pharmaceuticals, Inc., Celsion Corp.,

8.3 Alnylam Pharmaceuticals, Inc.,

8.4 ArQule, Inc.,

8.5 4SC AG,

8.6 ImClone Systems Inc.,

8.7 Jennerex Biotherapeutics, Inc.,

8.8 Pfizer Inc.,

8.9 F Hoffmann-La Roche Ltd..,

8.10 Bristol-Myers Squibb Company.

9. Appendix

9.1 Abbrevations

9.2 Sources

9.3 Bibliography

9.4 Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21 100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...

Cancer Drugs in the FDA Fast Lane: Analytical Tool

Cancer Drugs in the FDA Fast Lane: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

The future of the Vaccine Industry

  • October 2016
    3 pages
  • Vaccine  

  • United Kingdom  



View report >

Infectious Disease Statistics and Therapy Market in the US

  • October 2016
    77 pages
  • Infectious Dise...  



  • United States  

View report >

Therapy Market

9 days ago

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.